Results announcement for fourth quarter 2013

Issued Wednesday 5 February 2014, London UK

GSK announces core EPS of 112.2p and dividend of 78p

  • Core EPS of 112.2p (+4% CER) and dividend of 78p (+5%)
  • £5.2 billion of cash returned to shareholders through 5% increase in 2013 dividend to 78p, (Q4 23p) and repurchase of £1.5 billion of shares
  • Exceptional year for R&D delivery with approvals for six major products and five additional regulatory filings completed
  • New product launches strengthen businesses in Respiratory, Vaccines, HIV and Oncology

Pipeline opportunity remains substantial with Phase III data for six potential new drugs and vaccines and around ten NME Phase III starts across 2014 and 2015.

View full Q4 2013 results (PDF)

More details with CEO and CFO interview available in the quarterly results section of this website.

This press release is intended for business journalists and analysts/investors. Please note that this release may not have been issued in every market in which GSK operates.